化痰散瘀法联合化疗治疗中晚期食管癌30例临床观察  

Clinical Observation on Phlegm-Transforming Stasis-Dissipating Therapy Combined with Chemotherapy for 30 Cases of Advanced Esophageal Cancer

作　　者：马纯政[1] 王蓉[1] 张明智[2] 黄莉[1] 刘培民[1] 王怀璋[3] 

机构地区：[1]河南省中医院肿瘤科,河南省郑州市东风路6号450002 [2]郑州大学第一附属医院 [3]河南省肿瘤医院

出　　处：《中医杂志》2013年第15期1301-1303,1307,共4页Journal of Traditional Chinese Medicine

基　　金：河南省教育厅自然科学研究计划项目(2009A360011)

摘　　要：目的观察化痰散瘀法联合化疗治疗中晚期食管癌的临床疗效。方法将60例中晚期食管癌患者随机分为治疗组和对照组各30例;治疗组采用化疗加化痰散瘀法基本方加减,对照组仅给予化疗,两组均治疗21天为1个周期,共4个周期,观察两组患者治疗前后中医症状积分、KPS评分、肿瘤疗效及骨髓抑制情况。结果两组治疗后中医症状积分较治疗前明显下降、KPS评分升高(P<0.01);治疗后两组比较,治疗组中医症状积分降低优于对照组(P<0.01),治疗组KPS评分高于对照组(P<0.05)。治疗组肿瘤疗效缓解率为33.33%,稳定率为70.00%,对照组分别为26.67%、43.33%,两组比较缓解率差异无统计学意义(P>0.05),治疗组稳定率高于对照组(P<0.05)。两组患者骨髓抑制情况比较差异有统计学意义(P<0.05),治疗组优于对照组。结论化痰散瘀法联合化疗能改善中晚期食管癌患者临床症状,提高肿瘤稳定率,减轻化疗对骨髓的毒性。Objective To observe the therapeutic effect of phlegm-transforming stasis-dissipating therapy combined with chemotherapy on advanced esophageal cancer. Methods Sixty cases of advanced esophageal cancer were randomized into treatment group and control group, with 30 in each. The treatment group was given chemotherapy and modified phlegm-transforming stasis-dissipating formula. The control group was given chemotherapy only. Both groups were treated for 21 days as one treatment course. The treatment lasted for 4 courses. The TCM pattern score, Karnofsky performance score （KPS）, tumor response and inhibition of bone marrow were observed in both groups before and after treatment. Results The TCM pattern scores were significantly decreased but the KPS were significantly increased in both groups after treatment （P0.01）, especially in the treatment group （P0.01 or P0.05）. The remission rate and stability rate of tumor response in the treatment group was 33.33% and 70.00% respectively. The remission rate and stability rate of tumor response in the control group was 26.67% and 43.33% respectively. There was no significant difference between groups in the remission rate （P0.05）. The stability rate in the treatment group was significantly higher than that in the control group （P0.05）. The inhibition of bone marrow in the treatment group was superior to that in the control group （P0.05）. Conclusion The phlegm-transforming stasis-dissipating therapy can relieve the symptoms of advanced esophageal cancer, increase tumor stabilization rate and decrease the toxicity of chemotherapy on bone marrow.

关 键 词：食管癌 化痰散瘀法 化疗 骨髓抑制 

分 类 号：R273[医药卫生—中西医结合] R735.1[医药卫生—中医肿瘤科]